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ABSTRACT
High recurrence and lower survival rates in patients with oral squamous cell 
carcinoma (OSCC) are associated with its bone invasion. We identified the oncogenic 
role of RUNX3 during bone invasion by OSCC. Tumor growth and the generation 
of osteolytic lesions were significantly inhibited in mice that were subcutaneously 
inoculated with RUNX3-knockdown human OSCC cells. RUNX3 knockdown enhanced 
TGF-β-induced growth arrest and inhibited OSCC cell migration and invasion in the 
absence or presence of transforming growth factor-β (TGF-β), a major growth factor 
abundant in the bone microenvironment. RUNX3 knockdown induced cell cycle arrest 
at the G1 and G2 phases and promoted G2 arrest by TGF-β in Ca9.22 OSCC cells. 
RUNX3 knockdown also inhibited both the basal and TGF-β-induced epithelial-to-
mesenchymal transition by increasing E-cadherin expression and suppressing the 
nuclear translocation of β-catenin. In addition, the expression and TGF-β-mediated 
induction of parathyroid hormone-related protein (PTHrP), one of key osteolytic 
factors, was blocked in RUNX3-knockdown OSCC cells. Furthermore, treating human 
osteoblastic cells with conditioned medium derived from RUNX3-knockdown OSCC 
cells reduced the receptor activator of nuclear factor-kappaB ligand (RANKL)/
osteoprotegerin ratio compared with treatment with conditioned medium from 
RUNX3-expressing cells. These findings indicate that RUNX3 expression in OSCC 
cells contributes to their bone invasion and the resulting osteolysis by inducing 
their malignant behaviors and production of osteolytic factors. RUNX3 alone or 
in combination with TGF-β and PTHrP may be a useful predictive biomarker and 
therapeutic target for bone invasion by oral cancer.
INTRODUCTION
Oral cancer, a major subtype of head and neck 
cancers, is one of the 10 most commonly diagnosed 
cancers, and more than 90% of oral malignancies are 
squamous cell carcinomas (OSCC) [1, 2]. Despite the 
improved treatment of OSCC, the 5-year survival rate 
for oral cancer, approximately 63 percent, is less than 
the 5-year survival rate for all cancers [3]. Oral cancer 
readily invades the neighboring jawbone, which increases 
mortality [4]. When oral cancer directly invades the 
bone of the maxilla and/or the mandible, patients 
experience severe dysfunctions in speech, mastication, 
and/or swallowing and should be treated with a surgical 
resection of the jawbone, which causes severe physical 
and psychological problems [5]. In addition, bone invasion 
is a risk factor for mandibular osteoradionecrosis and thus 
must be considered when planning radiotherapy [6]. Since 
bone invasion is closely associated with poor prognosis 
in oral cancer, finding efficient predictive marker or 
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therapeutic target molecules is required for controlling 
OSCC bone invasion.
Transforming growth factor-β (TGF-β) is one of the 
growth factors abundant in the bone microenvironment. 
This factor is deposited in the bone matrix and released 
via bone resorption. The TGF-β released due to cancer-
induced osteolysis, as well as that released by stromal 
cells and cancer cells, stimulates tumors to increase 
the production of osteolytic factors and promote their 
invasiveness [4, 7, 8]. Although TGF-β has been 
considered to play dual roles in human cancer progression 
depending on the cellular context and the tumor stage, 
i.e., tumorigenic and tumor-suppressive roles [9], a recent 
study reported that TGF-β signaling may contribute to 
the bony invasion of oral cancer by modulating receptor 
activator of nuclear factor-kappaB ligand (RANKL), 
tumor necrosis factor-α, and connective tissue growth 
factor expression in oral cancer cells [10].
Runt-related transcription factor 3 (RUNX3) is a 
functionally important transcription factor of the TGF-
β-mediated signaling pathway [11]. RUNX3 acts as a 
tumor suppressor in many cancers, including stomach, 
bladder, breast, lung, brain, colorectal, pancreatic, and 
hepatocellular carcinoma [12, 13]. In these cancers, 
RUNX3 inhibits oncogenic Wnt signaling by interacting 
with β-catenin and promotes TGF-β-induced growth 
inhibition by interacting with SMAD3/SMAD4 [14]. 
In contrast, RUNX3 reportedly plays an oncogenic role in 
basal cell carcinoma and epithelial ovarian cancer [13]. In 
head and neck cancers, the role of RUNX3 is controversial. 
Several studies have demonstrated that RUNX3 expression 
correlates with the histologic differentiation grades of 
OSCCs, and the survival rate of patients with lower 
RUNX3 expression is significantly decreased compared 
with that of patients with higher expression [15, 16]. In 
addition, the inactivation of RUNX3 in OSCCs due to gene 
promoter hypermethylation is significantly associated with 
tumor stage and the presence of lymph node metastases 
[17]. Other studies have indicated an oncogenic function 
for RUNX3 in head and neck cancer [18]. RUNX3 
expression was not observed in normal oral mucosal 
tissues but was detected in 50% of head and neck cancer 
tissues. RUNX3 expression correlates well with poor 
differentiation, invasiveness, metastasis, and resistance 
to chemotherapeutic drugs [19]. However, the role of 
RUNX3 in bone invasion via interactions between oral 
cancer and the bone microenvironment remains unclear. 
The present study aimed to determine whether 
RUNX3 could serve as a predictive marker and/or 
therapeutic target to treat bone invasion in OSCC. We found 
that knocking down RUNX3 in Ca9.22 human OSCC cells 
reduced calvarial osteolysis in mice. This murine model 
with calvarial injection can be excluded from the stress such 
as mastication compared with orthotopic mouse models 
of OSCC and is thereby regarded as a suitable model 
for OSCC-induced osteolysis [20, 21]. Furthermore, we 
demonstrate that RUNX3 expression in OSCC cells plays 
a critical role in bone invasion and the resulting osteolysis 
by promoting the malignant behaviors of OSCC cells and 
osteoblastic RANKL expression.
RESULTS
RUNX3 knockdown inhibited tumor growth and 
bone loss in OSCC cell-injected mice
To examine the correlation of RUNX3 expression 
in oral cancer cells with tumor growth and cancer-
induced bone destruction, we first established stable 
RUNX3-knockdown (shRUNX3) Ca9.22 cells and its 
control (shCTRL) cells by transducing lentiviral particles 
with RUNX3 and non-specific short hairpin RNAs, 
respectively. The combined in vivo data were derived from 
two independent experiments (Supplementary Figure S1). 
Tumor growth was significantly inhibited by 63% in mice 
that were subcutaneously injected with shRUNX3 cells at 
the calvaria compared with mice inoculated with shCTRL 
cells (Figure 1A). The three-dimensional (3D) images from 
the μCT data showed that inoculation with shCTRL cells 
induced severe bone destruction, but RUNX3 knockdown 
inhibited bone destruction (Figure 1B). Among the values 
of the bone morphometric parameters, the bone volume/
tissue volume (BV/TV, %) and bone surface/tissue volume 
(BS/TV, 1/mm) were significantly decreased and the bone 
surface/bone volume (BS/BV, 1/mm) was increased in 
shCTRL cell-injected mice compared with control mice. 
BV/TV is one of the most important in revealing the 
microstructure of cancellous bone. BS/TV and BS/BV 
indicate bone surface density and bone-specific surface, 
respectively. RUNX3 knockdown recovered these values 
to almost control levels although the BS/BV value did 
not show the statistical significance between shCTRL and 
shRUNX3 cell-injected mice (Figure 1C). The serum levels 
of the bone metabolism markers calcium, tartrate-resistant 
acid phosphatase (TRAP), and alkaline phosphatase (ALP) 
were also higher in shCTRL cell-inoculated mice than 
in control mice. The levels of serum calcium and TRAP 
were inhibited significantly by RUNX3 knockdown. 
The serum ALP level was also decreased in shRUNX3 
cell-injected mice but not significantly different between 
shCTRL and shRUNX3 cell-injected mice (Figure 1D). 
Hematoxylin and eosin (H&E) staining indicated that 
bone was intermingled with tumor due to aggressive tumor 
growth and serious bone loss in shCTRL cell-injected 
mice, whereas a broad tumor front and clear interface 
between the bone and tumor were observed in shRUNX3 
cell-injected mice (Figure 1E). The immunohistochemical 
analysis revealed that Ki67 as a proliferation marker and 
CD31 as an endothelial cell marker were highly expressed 
in the tumor tissues of shCTRL cell-injected mice, but 
RUNX3 knockdown decreased the expression levels 
of these markers (Figure 1F). These results demonstrate 
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that RUNX3 may be an oncogenic protein in Ca9.22 
OSCC cells and play a part in oral cancer-induced bone 
destruction in vivo.
RUNX3 knockdown inhibited the malignant 
behaviors of oral cancer cells
Next, we investigated the possible link between 
RUNX3 expression and the malignant behaviors of 
OSCC cells. Noticeable morphological changes were not 
detected, but increased cell-cell contacts were observed 
in shRUNX3 cells compared with shCTRL Ca922 cells. 
TGF-β treatment reduced cell-cell contact in shCTRL 
cells but not in shRUNX3 cells (Figure 2A). Culturing 
shCTRL and shRUNX3 cells in the absence of TGF-β for 
24 h and 72 h did not result in significant differences in 
the viabilities of these cells. RUNX3 knockdown inhibited 
cell viability by 12% and 23% in Ca9.22 cells stimulated 
with TGF-β for 24 h and 72 h (Figure 2B). In the absence 
of TGF-β, RUNX-3 knockdown reduced cell migration 
and invasion by 38% (Figure 2C) and by 44% (Figure 2D), 
respectively. TGF-β stimulation for 24 h significantly 
increased the migration of shCTRL cells, not shRUNX3 
cells (Figure 2C) and promoted the invasion of shCTRL 
and shRUNX3 cells (Figure 2D). RUNX3 knockdown 
significantly inhibited TGF-β-induced cell invasion 
(Figure 2D). Furthermore, we investigated the effect of 
RUNX3 knockdown in YD10B cells, another RUNX3-
expressing OSCC cells (Supplementary Figure S2A). 
RUNX3 knockdown did not affect the viability 
(Supplementary Figure S2B). TGF β stimulation increased 
cell invasion by 23% in RUNX3-expressing siCTRL cells 
and by 11% in RUNX3 knockdown siRUNX3 cells. 
RUNX3 knockdown remarkably inhibited cell invasion 
in the absence or presence of TGF-β in YD10B cells 
(Supplementary Figure S2C). These results indicate that 
RUNX3 expression is associated with the malignant 
behavior of OSCC cells.
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RUNX3 knockdown promoted TGF-β-induced 
cell cycle arrest in Ca9.22 oral cancer cells
To further examine the effect of RUNX3 expression 
and TGF-β stimulation on the growth of Ca9.22 cells, 
the cell cycle distributions of shCTRL and shRUNX3 
cells were analyzed after treatment with TGF-β for 24 h. 
Compared with shCTRL cells, the cell populations in 
the sub-G1 and S phase were reduced, and those in G1 
and G2 phase were significantly increased in shRUNX3 
cells, irrespective of TGF-β treatment. TGF-β stimulation 
significantly increased the population of shRUNX3 cells 
in the G2 phase (Table 1). These results suggest that 
RUNX3 knockdown induced cell cycle arrest in the G1 
and G2 phases in Ca9.22 OSCC cells.
RUNX3 knockdown inhibited the epithelial-to-
mesenchymal transition (EMT) of OSCC cells
EMT is a process whereby epithelial cells are 
transcriptionally reprogrammed, resulting in decreased 
adhesion and enhanced migration or invasion [22, 23]. 
TGF-β also increases OSCC cell invasion by regulating 
EMT markers and stimulating the production of factors 
that prolong osteoclast survival [24]. To determine 
whether the decreases in migration and invasion were due 
to the inhibition of EMT in TGF-β-treated and untreated 
shRUNX3 Ca9.22 cells, we examined the expression 
levels of EMT markers. Western blot analysis indicated 
that TGF-β stimulation increased RUNX3 expression. 
The expression of E-cadherin, an epithelial marker, was 
Figure 1: The oncogenic potential of RUNX3 in cancer-induced bone destruction in vivo. hCTRL or shRUNX3 Ca9.22 
OSCC cells (1 × 107 cells/100 μl of HBSS) were subcutaneously injected at the mouse calvaria (N = 11). Control mice (N = 9) were injected 
with HBSS only. (A) RUNX3 expression level in wild type (WT), shCTRL, and shRUNX3 Ca9.22 cells was detected with a Western blot 
analysis with its specific primary antibody. On day 28, the tumor volumes were measured. (B) On day 28, two-dimensional (2D) images of 
the collected carvaria were generated from the μCT data using the NRrecon software, and 3D images were reconstructed from 2D images 
with the rapidform2006 software. (C) BV/TV (%), BS/TV (1/mm), and BS/BV (1/mm) served as bone morphometric parameters of the 
calvaria were determined using the μCT images. (D) Serum levels of the bone turnover markers Ca2+, ALP, and TRAP5b were estimated 
using kits as described in the Materials and Methods. (E, F) The calvarial tissues were fixed with 1% buffered formalin, decalcified in 
10% EDTA solution and sectioned. The sections were stained with H&E (original magnification, 100×) (E) and immunostained with 
specific antibodies against RUNX3, CD31, and Ki67 (original magnification, 200×) (F). Scale bar = 100 µm. Proliferative index and 
microvessel density were evaluated by immunostaining for Ki67 and CD31, respectively. The images are representative of two independent 
experiments. The results are combined data from two independent experiments and expressed as the median with interquartile range of 9 or 
11 mice per group. *P < 0.05, **P < 0.005 versus HBSS-injected control mice, #P < 0.05, ##P < 0.005 versus shCTRL cell-inoculated mice.
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increased in shRUNX3 cells and its reduced expression by 
TGF-β in shCTRL was not detected in shRUNX3 cells. 
RUNX3 knockdown did not affect the cellular level of 
β-catenin which is a mesenchymal marker (Figure 3A). 
Matrix metalloproteinase (MMP)-9 levels in the culture 
media were elevated in TGF-β-treated shCTRL cells but 
was decreased in shRUNX3 cells, whereas the MMP-
2 levels in the culture media were not influenced by 
RUNX3 knockdown or TGF-β treatment (Figure 3B). 
The translocation of β-catenin to the nucleus was 
promoted by TGF-β stimulation in shCTRL cells but 
was not increased in TGF-β-stimulated shRUNX3 cells 
(Figure 3C). Immunofluorescence images also showed that 
E-cadherin expression was decreased and the number of 
cells with the nuclear β-catenin was increased by TGF-β 
stimulation in shCTRL cells. The effect of TGF-β on 
E-cadherin and the nuclear translocation of β-catenin was 
not detected in shRUNX3 cells. E-cadherin and β-catenin 
Table 1: The effect of RUNX3 knockdown on the cell cycle distribution of oral cancer cells
Cell cycle
shCTRL cells shRUNX3 cells
TGF-β (–) TGF-β (+) TGF-β (–) TGF-β (+)
Sub-G1 3.1 ± 0.2 3.7 ± 0.5 2.2 ± 0.1* 2.6 ± 0.2
G1 42.9 ± 0.9 42.3 ± 0.8 47.2 ± 0.5* 46.2 ± 0.3#
S 43.4 ± 0.6 43.6 ± 0.3 39.1 ± 0.4* 38.1 ± 0.1#
G2 10.9 ± 0.04 11.7 ± 0.6 11.6 ± 0.2* 13.8 ± 0.2#,
shCTRL and shRUNX3 Ca9.22 cells (1 × 105 cells/dish) were treated with 10 ng/ml TGF-β for 24 h. Cell cycle analysis was 
performed using a FACSverse cytometer. Results are expressed as the mean ± S.E. *P < 0.05 versus shCTRL cells, #P < 0.05 
versus TGF-β-treated shCTRL cells, P < 0.0.5 versus shRUNX3 cells. 
Figure 2: The effect of RUNX3 knockdown on the viability, migration, and invasion of OSCC cells in the absence or 
presence of TGF-β. (A) shCTRL or shRUNX3 Ca9.22 cells (1 × 103 cells/well) were treated with 10 ng/ml TGF-β. Cells were observed 
with an inverted microscope after 24 h of incubation (original magnification, 100×), and (B) viability was determined using an MTT assay 
for cells treated for 24 h or 72 h. (C) Lower surface of the membrane was coated with gelatin (1 mg/ml in distilled water), and shCTRL and 
shRUNX3 Ca9.22 cells (1 × 104 cells/0.1 ml) were seeded into the upper chamber. (D) After the lower and upper surfaces of membrane 
were coated with gelatin and Matrigel (1 mg/ml in distilled water), respectively, shCTRL and shRUNX3 Ca9.22 cells (5 × 104 cells/0.1 ml) 
were seeded into the upper chamber. Complete medium containing 5% FBS and 10 ng/ml TGF-β was added to the upper chamber, and the 
lower chamber was filled with 0.6 ml of complete medium containing 10% FBS. After a 24-h incubation, the migrated or invaded cells 
were fixed and stained with hematoxylin. The number of migrated or invaded cells was counted and imaged using a Zeiss Axio imager 
microscope (original magnification, 200×). The results are expressed as the mean ± SE. *P < 0.05, **P < 0.01 versus shCTRL cells, #P < 0.05 
versus TGF-β-treated shCTRL cells, P < 0.05, P < 0.001 versus shRUNX3 cells.
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were mainly detected along the membranes in shRUNX3 
cells (Figure 3D). We further confirmed the effects of 
RUNX3 knockdown and TGF-β stimulation on EMT-
related markers in YD10B cells. E-cadherin expression 
was increased and not decreased by TGF-β stimulation 
in RUNX3 knockdown YD10B cells (Supplementary 
Figure S3). RUNX3 knockdown inhibited the cellular level 
(Supplementary Figure S3A) and the nuclear translocation 
Figure 3: The effect of RUNX3 knockdown on the expression of EMT markers by OSCC cells in the absence or presence 
of TGF-β. shCTRL or shRUNX3 Ca9.22 cells (1 × 105 cells/dish) were treated with 10 ng/ml TGF-β for 24 h. (A) The expression levels 
of RUNX3, E-cadherin, and β-catenin were examined in the total lysates with a Western blot analysis. GAPDH served as a loading control. 
(B) Conditioned media were collected, and the MMP-2 and MMP-9 activities were determined using gelatin zymography. (C) Cytoplasmic 
and nuclear protein extracts were prepared using a nuclear/cytosol fractionation kit. The levels of RUNX3 and β-catenin in each fraction 
were determined via Western blot analysis. Lamin served as a loading control for the nuclear fraction. The images are representative of three 
independent experiments. The graphs illustrate the ratio of the densitometric intensity of β-catenin after normalization to lamin or GAPDH. 
(D) Subcellular localization of E-cadherin and β-catenin was examined by confocal microscopy. The cells were double immunostained for 
E-cadherin (green) and β-catenin (red) and co-stained with DAPI for DNA. The fields shown were independently visualized by confocal 
microscopy, and three images were then overlaid (Merge). Cellular distribution of β-catenin was shown as percentage of shCTRL or 
shRUNX3 cells with its cytoplasmic (C > N), cytoplasmic and nuclear (C/N), and nuclear (N > C) localization.
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(Supplementary Figure S3B) of β-catenin, irrespective of 
TGF-β-stimulation. Immunofluorescence images supported 
that the effect of TGF-β on E-cadherin and β-catenin was 
also blocked by RUNX3 knockdown in YD10B OSCC 
cells (Supplementary Figure S3C). These results suggest 
that RUNX3 expression contributes to the induction of 
EMT in OSCC cells.
RUNX3 knockdown inhibited parathyroid 
hormone-related protein (PTHrP) expression 
in OSCC cells and RANKL expression in 
osteoblasts
Cancer-induced bone destruction is due to the action 
of osteoblasts and osteoclasts rather than the direct action of 
tumor cells. RANKL and its decoy receptor osteoprotegerin 
(OPG) are key factors in cancer-induced bone destruction. 
These factors modulate the differentiation and activation 
of osteoclasts, and their expression is regulated by 
cancer cell-derived osteolytic cytokines [4]. PTHrP has 
been recognized as a major osteolytic cytokine whose 
expression is induced by TGF-β during cancer-induced 
bone destruction [25]. Western blot analysis indicated 
that TGF-β stimulation upregulated PTHrP expression 
in Ca9.22 (Figure 4A) and YD10B cells (Supplementary 
Figure S4A) but RUNX3 knockdown inhibited PTHrP 
expression in these two OSCC cells stimulated with 
TGF-β or not. In addition, TGF-β stimulation significantly 
increased PTHrP levels in the culture media of RUNX-3 
expressing OSCC cells and TGF-β-induced PTHrP 
secretion was blocked RUNX3 knockdown (Figure 4B, 
Supplementary Figure S4B) Furthermore, RANKL 
expression (Figure 4C) and secretion (Figure 4D) in human 
hFOB1.19 osteoblastic cells increased by treatment with 
shCTRL cell-derived conditioned medium and increased 
further when the cells were treated with conditioned 
medium of TGF-β-stimulated shCTRL cells. In contrast, 
conditioned media of shRUNX3 cells or TGF-β-stimulated 
shRUNX3 cells did not affect RANKL expression and 
secretion in osteoblasts. Conditioned media of both TGF-β-
treated and untreated shCTRL and shRUNX3 cells did not 
affect OPG expression. However, the secreted OPG levels 
were reduced by conditioned media of both TGF-β-treated 
and untreated shCTRL but these reduction was blocked by 
RUNX3 knockdown (Figure 4D). These findings suggest 
that RUNX3 expression promotes PTHrP production in 
OSCC cells and thereby induces RANKL production and 
increased RANKL/OPG ratio in osteoblasts.
RUNX3 gene expression enhanced in head and 
neck squamous cell carcinoma (HNSCC)
To estimate the clinical significance of RUNX3 
expression, we analyzed The Cancer Genome Atlas 
(TCGA) microarray data. RUNX3 gene expression was 
significantly higher in HNSCC tissues than in normal 
tissues (Figure 5A) and in the most advanced stage IV with 
bone invasion than in other stages (Figure 5B). The gene 
expressions of TGF-β as a RUNX-regulating growth factor 
and PTHrP as a RUNX3-regulated osteolytic cytokine 
were also upregulated in HNSCC tissues than normal 
tissues (Figure 5A). In Kaplan-Meier survival analysis, 
high gene expression of RUNX3 in combination with 
those of TGF-β and PTHrP was significantly correlated 
with poor overall survival (Figure 5C). 
DISCUSSION
Bone invasion is a common characteristic of 
OSCC. In particular, gingival squamous cell carcinomas 
invade the mandible in 12 to 56% of patients to worsen 
the patient’s prognosis and finally cause death [26, 27]. 
Osteoclasts, rather than the carcinomas themselves, 
have been recognized as key players in bone destruction 
due to cancer invasion [28]. Thus, a number of clinical 
trials have focused on targeting factors derived from 
bone metabolism rather than tumor-derived factors 
[29]. However, novel cancer-specific biomarkers are 
required to detect bone invasion early and control the 
growth and invasive capacity of cancer cells, which 
modulate bone microenvironment by releasing osteolytic 
factors and ultimately cause osteoclast activation. Such 
biomarkers may improve clinical outcomes. Therefore, we 
investigated the potential of RUNX3 as a cancer-specific 
marker for OSCC-mediated bone invasion.
We identified the oncogenic role of RUNX3 in the 
growth and bone invasion of OSCC. The bone invasion 
and resultant osteolysis as well as the tumor volume were 
noticeably reduced in mice inoculated with Ca9.22 OSCC 
cells in which RUNX3 was knocked down, as supported 
by histological examination, bone morphometric μCT 
analyses, and the detection of bone turnover markers in the 
sera. Histologically, oral cancer is associated with two types 
of bone invasion [30]. The erosive type is characterized by 
a broad tumor front and sharp interface between the bone 
and tumor, whereas the infiltrative type is characterized 
by an irregular interface and finger-like projections of oral 
cancer into the bone. The median disease-free survival is 
5.5 years for OSCC patients with erosive bone invasion but 
1.5 years for patients with bone invasion [31]. Interestingly, 
Ca9.22 OSCC cells infiltrated the bone, but this bone 
invasion was inhibited by RUNX3 knockdown.
We attempted to verify the mechanism underlying 
the oncogenic role of RUNX3 in the bone invasion of 
OSCC cells. During the initial phase of bone invasion, 
cancer cells produce proteases to degrade the extracellular 
matrix and facilitate the entry of cancer cells into the soft 
tissues or marrow spaces within the bone. The cancer 
cells then release cytokines to directly or indirectly induce 
excessive osteoclastogenesis. Finally, osteoclast-mediated 
bone resorption results in the release of several growth 
factors, and these factors stimulate cancer cells [20]. 
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Among these growth factors, TGF-β has been considered 
essential to the bony invasion of oral cancer [10]. In 
our study, RUNX3 knockdown and TGF-β stimulation 
resulted in the distinctive responsiveness to TGF-β in the 
viability of Ca9.22 and YD10B OSCC. However, RUNX3 
knockdown reduced noticeably the invasive capacity of 
both OSCC cells in the absence or presence of TGF-β, 
as supported by the enhanced E-cadherin expression and 
the reduced nuclear level of β-catenin compared with 
RUNX3-expressing cells. These changes in the expression 
levels of EMT markers are consistent with the reduced 
invasion in RUNX3-knockdown OSCC cells.
To investigate the mechanism by which RUNX3 
expression in OSCC cells could cause osteolysis, 
Figure 4: The effect of RUNX3 knockdown on the expression of PTHrP in OSCC cells and RANKL expression in 
osteoblasts. (A) shCTRL or shRUNX3 Ca9.22 cells (1 × 105 cells/dish) were treated with 10 ng/ml TGF-β for 24 h. The expression level 
of PTHrP was examined in the total lysates with a Western blot analysis. GAPDH served as a loading control. (B) shCTRL or shRUNX3 
Ca9.22 cells (1 × 103 cells/well) were treated with 10 ng/ml TGF-β for 24 h. PTHrP levels in the conditioned media were analyzed with a 
ELISA kit. The results are expressed as the mean ± SE. *P < 0.05 versus shCTRL cells without TGF-β. (C) hFOB1.19 osteoblastic cells 
(1 × 106 cells/dish) were incubated with the respective shCTRL or shRUNX3 Ca9.22 cell-derived conditioned media for 6 h. The expression 
levels of RANKL and OPG in osteoblastic cells were determined with a Western blot analysis. GAPDH served as a loading control. 
(D) hFOB1.19 cells (1 × 104 cells/well) were incubated for 24 h with or without conditioned media derived from shCTRL or shRUNX3 
Ca9.22 cells. The culture media from hFOB1.19 cells were analyzed for the secreted levels of RANKL and OPG with ELISA kits. The 
results are expressed as the mean ± SE. *P < 0.05 versus control (without conditioned media), #P < 0.05 versus conditioned media derived 
from untreated shCTRL cells.
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we focused on the role of RUNX3 and TGF-β in 
the interactions between oral cancer and the bone 
microenvironment. RUNX3 knockdown inhibited PTHrP 
production and the induction of PTHrP by TGF-β in OSCC 
cells. Moreover, RUNX3 knockdown in OSCC cells 
inhibited osteoblastic RANKL production. These results 
suggest that the production of PTHrP via RUNX3 in OSCC 
mediates osteoblastic RANKL and OPG production. The 
enhanced RANKL expression and RANKL/OPG ratio 
are well-known factors that promote bone resorption by 
triggering osteoclast formation [32–34].
Finally, the gene expression levels of RUNX3, 
TGF-β (a RUNX3-regulating growth factor), and PTHrP 
(a RUNX3-regulated osteolytic factor) were higher in the 
tissues of patients with head and neck cancer, including 
oral cancers, than in normal tissues. The increased 
RUNX3 gene expression in the most advanced tumor 
stage, stage IV, with bone invasion is consistent with our 
in vitro and in vivo data suggesting the oncogenic role of 
RUNX3 in oral cancer bone invasion.
In summary, RUNX3 participates in cancer-induced 
bone destruction by affecting the survival, migration, 
invasion, and/or TGF-β responsiveness of OSCC cells 
and by increasing the production of PTHrP by OSCC 
cells (Figure 6). RUNX3 independently or in combination 
with TGF-β and PTHrP may serve as a biomarker for 
predicting the prognosis of and potential for bone invasion 
in oral cancer patients, and it may also serve as a potential 
therapeutic target for controlling cancer invasion.
MATERIALS AND METHODS
Reagents and antibodies
Dulbecco’s modified Eagle’s medium (DMEM), 
Ham’s F-12 nutrient mixture, Dulbecco’s modified Eagle’s 
medium nutrient mixture F-12 (DMEM/F-12) without 
phenol red, fetal bovine serum (FBS), Hank’s balanced 
salt solution (HBSS), phosphate-buffered saline (PBS), 
antibiotic-antimycotic mixture containing 100 U/ml 
penicillin and 100 µg/ml streptomycin, Geneticin® (G418), 
and 0.25% trypsin-EDTA were purchased from Gibco BRL 
(Grand Island, NY, USA). Recombinant human TGF- β1 
was obtained from Millipore (Billerica, MA, USA). 
Cholera toxin, hydrocortisone, insulin, apo-transferrin, 
triiodothyronine (T3), 3-(4,5-dimethylthiazol-2yl)-2,5-
diphenyl tetrazolium bromide (MTT), and propidium 
iodide (PI) were purchased from Sigma-Aldrich Chemical 
(St. Louis, MO, USA). The antibodies were obtained from 
the following sources: polyclonal anti-rabbit antibodies 
against E-cadherin, β-catenin, RANKL, and PTHrP, 
monoclonal anti-mouse antibodies against OPG and 
Figure 5: The relationship between oral cancer and the expression levels of RUNX3, TGF-β and PTHrP. (A) Box and 
whisker plots show the expression level of RUNX3, TGF-β and PTHrP. Box represents the median and the quartiles. Whisker expresses 1.5 
interquartile range (IQR) of the lower or the upper quartile. (B) The expression level of RUNX3 grouped by tumor stage was examined. 
(C) Kaplan–Meier survival curves show the probability of overall survival in relation to the expression of RUNX3, TGF-β, PTHrP and 
the combination of expression level of three genes in patients with head and neck cancer. For each gene, the head and neck cancers were 
classified into high- or low-expressing groups according to whether the expression of the candidate gene was greater than the median 
expression of the gene. *P < 0.001 versus normal.
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glyceraldehyde 3-phosphate dehydrogenase (GAPDH), 
and horseradish peroxidase (HRP)-conjugated secondary 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, 
USA); anti-mouse E-cadherin monoclonal antibody (BD 
Biosciences, San Jose, CA, USA); anti-mouse RUNX3 
monoclonal (catalog #ab40278), anti-rabbit CD31 
polyclonal (ab28364), and anti-rabbit Ki67 polyclonal 
(catalog #ab15580) antibodies (Abcam, Cambridge, 
UK); anti-rabbit β-actin polyclonal antibody (Sigma-
Aldrich); and HRP-goat anti-mouse/anti-rabbit IgG (H+L, 
Invitrogen, Carlsbad, CA, USA). All reagents used in this 
study were of analytical grade.
Cell culture
Ca9.22 cells derived from human gingival squamous 
cell carcinoma were purchased from the Japanese 
Collection of Research Bioresources Cell Bank (Shinjuku, 
Japan), and the cells were grown in DMEM/F12 (3:1 ratio) 
medium supplemented with 10% FBS, 1 × 10–10 M cholera 
toxin, 0.4 mg/ml hydrocortisone, 5 μg/ml insulin, 5 μg/ml 
apo-transferrin, and 2 × 10–11 M T3 in a humidified 
atmosphere of 5% CO2 at 37°C. hFOB1.19 human fetal 
osteoblastic cells were cultured in DMEM/F12 without 
phenol red with 10% FBS, 1% antibiotic-antimycotic 
mixture and 0.3 mg/ml G418 at 34°C under humidified 
atmosphere of 5% CO2.
Animals
Five-week-old male Balb/c nu/nu mice (19 ± 1 g) 
were obtained from the NARA Biotech (Seoul, Korea) and 
acclimatized for 1 week. Mice were provided access to 
a commercial rodent chow and tap water ad libitum and 
housed under specific pathogen-free conditions with a 
relative humidity of 50 ± 5% and a 12-h light/dark cycle 
at 22 ± 2°C. All animal experiments were approved by 
the Institutional Animal Care and Use Committee of the 
Department of Laboratory Animal Resources, Yonsei 
Biomedical Research Institute, Yonsei University College 
of Medicine (Approval number: 2013–0066).
RUNX3 knockdown
Ca9.22 cells were transduced with RUNX3 short 
hairpin RNA (shRNA) lentiviral particles (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) (shRUNX3 cells) 
or non-specific shRNA lentiviral particles (Santa Cruz 
Biotechnology) (shCTRL cells) as a control. Briefly, 
Ca9.22 cells were seeded at 1 × 105 cells per 60-mm dish 
24 h prior to viral infection. The cells were then infected 
with viral supernatants in the presence of 10 μg/ml 
polybrene for 24 h. The infected cells were maintained 
in fresh complete medium for 24 h and then cultured in 
complete medium containing puromycin (10 μg/ml) for 
an additional 2 weeks. Puromycin-resistant clones were 
selected and expanded. The level of RUNX3 in shCTRL 
and shRUNX3 Ca9.22 cells was determined via Western 
blot analysis.
A murine calvarial model for cancer-induced 
bone destruction
shCTRL or shRUNX3 Ca9.22 cells (1 × 107 cells/ 
100 μl of HBSS) were subcutaneously injected over the 
calvaria of mice (n = 5 or 6) using a 1-ml syringe with 
Figure 6: The oncogenic role of RUNX3 in the bone invasion of Ca9.22 OSCC cells is summarized.
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a sterile 26-gauge needle. The control group (n = 3 or 6) 
was injected with only HBSS. On day 28, the tumor 
volumes were measured using an electric digital caliper 
and calculated according to the following formula: tumor 
volume (mm3) = (a × b2)/2, where ‘a’ is the longest diameter 
and ‘b’ is the shortest diameter of the tumor. The mice 
were anesthetized by intraperitoneal injection of 30 mg/kg 
Zoletil (Virbac Laboratories, Carros, France) and 10 mg/kg 
Rompun (Bayer HealthCare Korea, Seoul, Korea) 
mixture. The blood was collected by cardiac puncture and 
the calvaria were collected after cervical dislocation.
The collected calvaria were analyzed scanned 
with a μCT system (SkyScan 1076, SkyScan, Aartselaar, 
Belgium) as described previously [35]. To quantitatively 
analyze bone destruction, the bone volume/tissue volume 
(BV/TV, %), bone surface/tissue volume (BS/TV, 1/mm), 
bone surface/bone volume (BS/BV, 1/mm) within the 
volume of interest (VOI) were obtained using the CTAn 
software (SkyScan).
The collected blood samples were clotted at room 
temperature for 2 h and centrifuged at 900 × g for 20 min 
to obtain sera. The serum levels of calcium and alkaline 
phosphatase (ALP) were measured using a QuantiChrome 
Calcium and ALP assay kit (BioAssay Systems, Hayward, 
CA, USA) and the serum level of tartrate-resistant acid 
phosphatase (TRAP) 5b was determined with a mouse 
TRAP assay kit (Immunodiagnostic Systems, Boldon, 
UK) according to the manufacturer’s instructions.
Paraffin-embedded calvarial tissues were serially 
sectioned (4-μm thick), mounted on slides, deparaffinized 
in xylene, rehydrated, and stained with hematoxylin and 
eosin (H&E). The stained tissues were then dehydrated 
and mounted with Shandon Synthetic Mountant solution 
(Thermo Scientific, Waltham, MA, USA). For the 
immunohistochemical examination, the rehydrated 
sections were treated with Digest-All 3 pepsin solution 
(Life Technologies, Grand Island, NY, USA) for 20 min 
at 37°C, 3% hydrogen peroxide for 15 min at room 
temperature, and goat serum for 30 min. The sections were 
incubated with a 1:100 dilution of each primary antibody 
against RUNX3, CD31, and Ki67 at 4°C overnight and 
then treated with HRP-conjugated secondary antibodies 
diluted 1:200 for 1 h at room temperature; the HRP activity 
was then determined using a DAB system (Lab Vision, 
Fremont, CA, USA). The sections were counterstained 
with Mayer’s hematoxylin, dehydrated, mounted, and 
observed under a Zeiss Axio imaging microscope.
Cell viability assay
shCTRL and shRUNX3 Ca9.22 cells (1 × 103 cells/
well) were seeded into a 96-well plate and incubated in 
complete media for 24 and 72 h with or without TGF-β 
(10 ng/ml). Cell viability was measured with an MTT 
assay (Jun et al., 2014).
Transwell migration and invasion assay
The migratory and invasive ability of shCTRL and 
shRUNX3 Ca9.22 cells was determined using a 6.5-mm 
transwell chamber with an 8.0-μm pore polycarbonate 
membrane (Corning Costar, Lowell, MA). For the 
migration assay, the lower surface of membrane was 
coated with gelatin (1 mg/ml in distilled water), and 
shCTRL and shRUNX3 Ca9.22 cells (1 × 104 cells/0.1 ml) 
were seeded into the upper chamber. For the invasion 
assay, the lower and upper surfaces of the membrane were 
coated with gelatin and Matrigel (1 mg/ml in distilled 
water), respectively. shCTRL and shRUNX3 Ca9.22 cells 
(5 × 104 cells/0.1 ml) were seeded into the upper chamber. 
The complete medium containing 5% FBS and 10 ng/ml 
TGF-β was added to the upper chamber, and the lower 
chamber was filled with 0.6 ml of complete medium 
containing 10% FBS. After a 24-h incubation, the number 
of the migrated or invaded cells was counted as described 
previously [35]. 
Cell cycle distribution analysis
shCTRL and shRUNX3 cells (1 × 105 cells/dish) 
were seeded in 100-mm culture dishes, and attached cells 
were treated with 10 ng/ml TGF-β for 24 h. The cells were 
trypsinized, resuspended in PBS, and fixed in 70% ethanol 
for 12 h. The cells were then stained with 0.1% (v/v) 
Triton X-100, 0.02 mg/ml PI, and 0.1 mg/ml RNase A for 
30 min. PI-stained cells were analyzed with a FACSverse 
cytometer (BD Bioscience, Franklin Lakes, NJ, USA).
Preparation of conditioned media
shCTRL and shRUNX3 Ca9.22 cells (1 × 105 cells/
dish) were seeded in 100-mm culture dishes for 24 h. The 
culture medium was changed to serum-free DMEM/F12, 
and the cells were treated with TGF-β for 24 h. The culture 
media were collected and centrifuged at 500 × g for 5 min. 
The supernatant served as the conditioned medium for 
subsequent experiments.
Western blot analysis
shCTRL and shRUNX3 Ca9.22 cells (1 × 105 cells/
dish) were seeded in 100-mm culture dishes and incubated 
with or without TGF-β at 37°C for 24 h. hFOB1.19 cells 
(1 × 106 cells/dish) were incubated for 6 h with 70% 
conditioned media obtained from shCTRL and shRUNX3 
Ca9.22 cells. The total cell lysates were prepared using 
RIPA buffer containing protease inhibitor cocktail (Roche 
Diagnostics, Penzberg, Germany) and centrifuged at 
22,000 × g for 15 min at 4°C. The cytoplasmic and nuclear 
protein extracts were prepared using a nuclear/cytosol 
fractionation kit (BioVision, Mountain View, CA, USA). 
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The target proteins were detected with 1:1,000 dilutions 
of the corresponding primary antibodies as described 
previously [36].
Gelatin zymography
shCTRL and shRUNX3 Ca9.22 cells (1 × 105 cells/
dish) were seeded in 100-mm culture dishes and incubated 
with or without 10 ng/ml TGF-β for 24 h. The culture 
media were collected by centrifugation at 200 × g for 5 min. 
The media were electrophoresed in a 8% polyacrylamide 
gel containing 0.8 mg/ml gelatin. The gels were washed 
with 2.5% Triton X-100 for 1 h at room temperature and 
incubated in a reaction buffer containing 50 mM Tris-HCl 
(pH 7.5), 5 mM CaCl2, 200 mM NaCl and 0.02% Brij35 
at 37°C for 24 h. The gels were then stained with 0.1% 
Coomassie Blue R-250, and the gelatinase activities of 
MMP-2 and MMP-9 were determined based on the clear 
bands against the Coomassie-stained background.
Immunofluorescence staining and confocal 
imaging
shCTRL and shRUNX3 Ca9.22 cells (1 × 103 cells/
well) were seeded into a chamber slide and incubated 
in complete media for 24 h with or without TGF-β 
(10 ng/ml). The cells were fixed with 4% paraformaldehyde 
(w/v), and permeabilized with Triton X-100 buffer. After 
blocking with 2% goat serum in PBS, the cells were 
incubated with anti-E-cadherin (BD Biosciences) and anti-
β-catenin (Santa Cruz Biotechnology) overnight at 4°C. 
After washing, the cells were incubated with Alexa Fluor 
488 goat anti-mouse IgG and Alexa Fluor 594 goat anti-
rabbit IgG (Invitrogen) for 1 h at room temperature. The 
slide was mounted using Vectashield mounting medium 
with DAPI (Vector Laboratories, CA, USA). The images 
were collected using a Zeiss LSM 700 confocal microscope.
Enzyme-linked immunosorbent assay
The secreted levels of PTHrP, RANKL, and OPG 
were measured with enzyme-linked immunosorbent 
assay (ELISA). shCTRL or shRUNX3 Ca9.22 cells 
(1 × 103 cells/well) were seeded into a 96-well plate and 
incubated for 24 h with or without TGF-β (10 ng/ml). The 
culture media were used for the measurement of secreted 
PTHrP level using commercially available ELISA kit 
(EIAab, Wuhan, China) according to the manufacturer’s 
recommendations. hFOB1.19 cells (1 × 104 cells/well) 
were seeded into a 96-well plate and incubated for 24 h 
with conditioned media from shCTRL or shRUNX3 
Ca9.22 cells stimulated with or without TGF-β. The 
culture media from hFOB1.19 cells were analyzed for 
the secreted levels of RANKL and OPG using RANKL 
ELISA kit (EIAab, Wuhan, China) and OPG ELISA kit 
(Boster Biological Technology, CA, USA) according to 
the manufacturer’s instructions. 
Public database analysis
The head and neck dataset from TCGA Research 
Network (http://cancergenome.nih.gov/) was analyzed for 
RUNX3, TGF-β, and PTHrP expression. Kaplan–Meier 
survival analysis was performed using SPSS 23 (IBM 
SPSS, Armonk, NY, USA). The patient samples have been 
split into higher and lower expression groups using the 
following setting of best cutoff. P values were calculated 
by a log rank test.
Statistical analyses
The results are expressed as the mean ± standard 
error (SE) and were analyzed with a one-way analysis 
of variance (ANOVA) and Student’s t-test to express the 
differences between two groups. Dot plots were presented 
using GraphPad Prism 7 (GraphPad Software, San diego, 
CA, USA). A p value < 0.05 was considered significant.
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